- •Preface and Acknowledgments
- •Contents
- •Contributors
- •1: Embryology for Urologists
- •Introduction
- •Renal Development
- •Pronephros
- •Mesonephros
- •Metanephros
- •Development of the Collecting System
- •Critical Steps in Further Development
- •Anomalies of the Kidney
- •Renal Agenesis
- •Renal Aplasia
- •Renal Hypoplasia
- •Renal Ectopia
- •Renal Fusion
- •Ureteral Development
- •Anomalies of Origin
- •Anomalies of Number
- •Incomplete Ureteral Duplication
- •Complete Ureteral Duplication
- •Ureteral Ectopia
- •Embryology of Ectopia
- •Clinical Correlation
- •Location of Ectopic Ureteral Orifices – Male (in Descending Order According to Incidence)
- •Symptoms
- •Ureteroceles
- •Congenital Ureteral Obstruction
- •Pipestem Ureter
- •Megaureter-Megacystis Syndrome
- •Prune Belly Syndrome
- •Vascular Ureteral Obstructions
- •Division of the Urogenital Sinus
- •Bladder Development
- •Urachal Anomalies
- •Cloacal Duct Anomalies
- •Other Bladder Anomalies
- •Bladder Diverticula
- •Bladder Extrophy
- •Gonadal Development
- •Testicular Differentiation
- •Ovarian Differentiation
- •Gonadal Anomalies
- •Genital Duct System
- •Disorders of Testicular Function
- •Female Ductal Development
- •Prostatic Urethral Valves
- •Gonadal Duct Anomalies
- •External Genital Development
- •Male External Genital Development
- •Female External Genital Development
- •Anomalies of the External Genitalia
- •References
- •2: Gross and Laparoscopic Anatomy of the Upper Urinary Tract and Retroperitoneum
- •Overview
- •The Kidneys
- •The Renal Vasculature
- •The Renal Collecting System
- •The Ureters
- •Retroperitoneal Lymphatics
- •Retroperitoneal Nerves
- •The Adrenal Glands
- •References
- •3: Gross and Laparoscopic Anatomy of the Lower Urinary Tract and Pelvis
- •Introduction
- •Female Pelvis
- •Male Pelvis
- •Pelvic Floor
- •Urinary Bladder
- •Urethra
- •Male Urethra
- •Female Urethra
- •Sphincter Mechanisms
- •The Bladder Neck Component
- •The Urethral Wall Component
- •The External Urethral Sphincter
- •Summary
- •References
- •4: Anatomy of the Male Reproductive System
- •Testis and Scrotum
- •Spermatogenesis
- •Hormonal Regulation of Spermatogenesis
- •Genetic Regulation of Spermatogenesis
- •Epididymis and Ductus Deferens
- •Accessory Sex Glands
- •Prostate
- •Seminal Vesicles
- •Bulbourethral Glands
- •Penis
- •Erection and Ejaculation
- •References
- •5: Imaging of the Upper Tracts
- •Anatomy of the Upper Tracts and Introduction to Imaging Modalities
- •Introduction
- •Renal Upper Tract Basic Anatomy
- •Modalities Used for Imaging the Upper Tracts
- •Ultrasound
- •Radiation Issues
- •Contrast Issues
- •Renal and Upper Tract Tumors
- •Benign Renal Tumors
- •Transitional Cell Carcinoma
- •Renal Mass Biopsy
- •Renal Stone Disease
- •Ultrasound
- •Plain Radiographs and IVU
- •Renal Cystic Disease
- •Benign Renal Cysts
- •Hereditary Renal Cystic Disease
- •Complex Renal Cysts
- •Renal Trauma
- •References
- •Introduction
- •Pathophysiology
- •Susceptibility and Resistance
- •Epidemiological Breakpoints
- •Clinical Breakpoints
- •Pharmacodynamic Parameters
- •Pharmacokinetic Parameters
- •Fosfomycin
- •Nitrofurantoin
- •Pivmecillinam
- •b-Lactam-Antibiotics
- •Penicillins
- •Cephalosporins
- •Carbapenems
- •Aminoglycosides
- •Fluoroquinolones
- •Trimethoprim, Cotrimoxazole
- •Glycopeptides
- •Linezolid
- •Conclusion
- •References
- •7: An Overview of Renal Physiology
- •Introduction
- •Body Fluid Compartments
- •Regulation of Potassium Balance
- •Regulation of Acid–Base Balance
- •Diuretics
- •Suggested Reading
- •8: Ureteral Physiology and Pharmacology
- •Ureteral Anatomy
- •Modulation of Peristalsis
- •Ureteral Pharmacology
- •Conclusion
- •References
- •Introduction
- •Afferent Signaling Pathways
- •Efferent Signaling
- •Parasympathetic Nerves
- •Sympathetic Nerves
- •Vesico-Spinal-Vesical Micturition Reflex
- •Peripheral Targets
- •Afferent Signaling Mechanisms
- •Urothelium
- •Myocytes
- •Cholinergic Receptors
- •Muscarinic Receptors
- •Nicotinic Receptors
- •Adrenergic Receptors (ARs)
- •a-Adrenoceptors
- •b-Adrenoceptors
- •Transient Receptor Potential (TRP) Receptors
- •Phosphodiesterases (PDEs)
- •CNS Targets
- •Opioid Receptors
- •Serotonin (5-HT) Mechanisms
- •g-Amino Butyric Acid (GABA) Mechanisms
- •Gabapentin
- •Neurokinin and Neurokinin Receptors
- •Summary
- •References
- •10: Pharmacology of Sexual Function
- •Introduction
- •Sexual Desire/Arousal
- •Endocrinology
- •Steroids in the Male
- •Steroids in the Female
- •Neurohormones
- •Neurotransmitters
- •Dopamine
- •Serotonin
- •Pharmacological Strategies
- •CNS Drugs
- •Enzyme-inducing Antiepileptic Drugs
- •Erectile Function
- •Ejaculatory Function
- •Premature Ejaculation
- •Abnormal Ejaculation
- •Conclusions
- •References
- •Epidemiology
- •Calcium-Based Urolithiasis
- •Uric Acid Urolithiasis
- •Infectious Urolithiasis
- •Cystine-Based Urolithiasis
- •Aims
- •Who Deserves Metabolic Evaluation?
- •Metabolic Workup for Stone Producers
- •Medical History and Physical Examination
- •Stone Analysis
- •Serum Chemistry
- •Urine Evaluation
- •Urine Cultures
- •Urinalysis
- •Twenty-Four Hour Urine Collections
- •Radiologic Imaging
- •Medical Management
- •Conservative Management
- •Increased Fluid Intake
- •Citrus Juices
- •Dietary Restrictions
- •Restricted Oxalate Diet
- •Conservative Measures
- •Selective Medical Therapy
- •Absorptive Hypercalciuria
- •Thiazide
- •Orthophosphate
- •Renal Hypercalciuria
- •Primary Hyperparathyroidism
- •Hyperuricosuric Calcium Oxalate Nephrolithiasis
- •Enteric Hyperoxaluria
- •Hypocitraturic Calcium Oxalate Nephrolithiasis
- •Distal Renal Tubular Acidosis
- •Chronic Diarrheal States
- •Thiazide-Induced Hypocitraturia
- •Idiopathic Hypocitraturic Calcium Oxalate Nephrolithiasis
- •Hypomagnesiuric Calcium Nephrolithiasis
- •Gouty Diathesis
- •Cystinuria
- •Infection Lithiasis
- •Summary
- •References
- •12: Molecular Biology for Urologists
- •Introduction
- •Inherited Changes in Cancer Cells
- •VEGR and Cell Signaling
- •Targeting mTOR
- •Conclusion
- •References
- •13: Chemotherapeutic Agents for Urologic Oncology
- •Introduction
- •Bladder Cancer
- •Muscle Invasive Bladder Cancer
- •Metastatic Bladder Cancer
- •Conclusion
- •Prostate Cancer
- •Other Chemotherapeutic Drugs or Combinations for Treating HRPC
- •Conclusion
- •Renal Cell Carcinoma
- •Chemotherapy
- •Immunotherapy
- •Angiogenesis Inhibitor Drugs
- •Conclusion
- •Testicular Cancer
- •Stage I Seminoma
- •Stage I non-seminomatous Germ Cell Tumours (NSGCT)
- •Metastatic Germ Cell Tumours
- •Low-Volume Metastatic Disease (Stage II A/B)
- •Advanced Metastatic Disease
- •Salvage Chemotherapy for Relapsed or Refractory Disease
- •Conclusion
- •Penile Cancer
- •Side Effects of Chemotherapy
- •Conclusion
- •References
- •14: Tumor and Transplant Immunology
- •Antibodies
- •Cytotoxic and T-helper Cells
- •Immunosuppression
- •Induction Therapy
- •Maintenance Therapy
- •Rejection
- •Posttransplant Lymphoproliferative Disease
- •Summary
- •References
- •15: Pathophysiology of Renal Obstruction
- •Causes of Renal Obstruction
- •Effects on Prenatal Development
- •Prenatal Hydronephrosis
- •Spectrum of Renal Abnormalities
- •Renal Functional Changes
- •Renal Growth/Counterbalance
- •Vascular Changes
- •Inflammatory Mediators
- •Glomerular Development Changes
- •Mechanical Stretch of Renal Tubules
- •Unilateral Versus Bilateral
- •Limitations of Animal Models
- •Future Research
- •Issues in Patient Management
- •Diagnostic Imaging
- •Ultrasound
- •Intravenous Urography
- •Antegrade Urography and the Whitaker Test
- •Nuclear Renography
- •Computed Tomography
- •Magnetic Resonance Urography
- •Hypertension
- •Postobstructive Diuresis
- •References
- •Introduction
- •The Normal Lower Urinary Tract
- •Anatomy
- •Storage Function
- •Voiding Function
- •Neural Control
- •Symptoms
- •Flow Rate and Post-void Residual
- •Voiding Cystometry
- •Male
- •Female
- •Neurourology
- •Conclusions
- •References
- •17: Urologic Endocrinology
- •The Testis
- •Normal Androgen Metabolism
- •Epidemiological Aspects
- •Prostate
- •Brain
- •Muscle Mass and Adipose Tissue
- •Bones
- •Ematopoiesis
- •Metabolism
- •Cardiovascular System
- •Clinical Assessment
- •Biochemical Assessment
- •Treatment Modalities
- •Oral Preparations
- •Parenteral Preparations
- •Transdermal Preparations
- •Side Effects and Treatment Monitoring
- •Body Composition
- •Cognitive Decline
- •Bone Metabolism
- •The Kidneys
- •Endocrine Functions of the Kidney
- •Erythropoietin
- •Calcitriol
- •Renin
- •Paraneoplastic Syndromes
- •Hypercalcemia
- •Hypertension
- •Polycythemia
- •Other Endocrine Abnormalities
- •References
- •General Physiology
- •Prostate Innervation
- •Summary
- •References
- •Wound Healing
- •Inflammation
- •Proliferation
- •Remodeling
- •Principles of Plastic Surgery
- •Tissue Characteristics
- •Grafts
- •Flap
- •References
- •Lower Urinary Tract Symptoms
- •Storage Phase
- •Voiding Phase
- •Return to Storage Phase
- •Urodynamic Parameters
- •Urodynamic Techniques
- •Volume Voided Charts
- •Pad Testing
- •Typical Test Schedule
- •Uroflowmetry
- •Post Voiding Residual
- •Further Diagnostic Evaluation of Patients
- •Cystometry with or Without Video
- •Cystometry
- •Videocystometrography (Cystometry + Cystourethrography)
- •Cystometric Findings
- •Comment:
- •Measurements During the Storage Phase:
- •Measurements During the Voiding Phase:
- •Abnormal Function
- •Disorders of Sensation
- •Causes of Hypersensitive Bladder Sensation
- •Causes of Hyposensitive Bladder Sensation
- •Disorders of Detrusor Motor Function
- •Bladder Outflow Tract Dysfunction
- •Detrusor–Urethral Dyssynergia
- •Detrusor–Bladder Neck Dyssynergia
- •Detrusor–Sphincter Dyssynergia
- •Complex Urodynamic Investigation
- •Urethral Pressure Measurement
- •Technique
- •Neurophysiological Evaluation
- •Conclusion
- •References
- •Endoscopy
- •Cystourethroscopy
- •Ureteroscopy and Ureteropyeloscopy
- •Nephroscopy
- •Virtual Reality Simulators
- •Lasers
- •Clinical Application of Lasers
- •Condylomata Acuminata
- •Urolithiasis
- •Benign Prostatic Hyperplasia
- •Ureteral and Urethral Strictures
- •Conclusion
- •References
- •Introduction
- •The Prostatitis Syndromes
- •The Scope of the Problem
- •Category III CP/CPPS
- •The Goal of Treatment
- •Conservative Management
- •Drug Therapy
- •Antibiotics
- •Anti-inflammatories
- •Alpha blockers
- •Hormone Therapies
- •Phytotherapies
- •Analgesics, muscle relaxants and neuromodulators
- •Surgery
- •A Practical Management Plan
- •References
- •Orchitis
- •Definition and Etiology
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation
- •Treatment of Infectious Orchitis
- •Epididymitis
- •Definition and Etiology
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation of Epididymitis
- •Treatment of Acute Epididymitis
- •Treatment of Chronic Epididymitis
- •Treatment of Spermatic Cord Torsion
- •Fournier’s Gangrene
- •Definition and Etiology
- •Risk Factors
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation
- •Treatment
- •References
- •Fungal Infections
- •Candidiasis
- •Aspergillosis
- •Cryptococcosis
- •Blastomycosis
- •Coccidioidomycosis
- •Histoplasmosis
- •Radiographic Findings
- •Treatment
- •Tuberculosis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Schistosomiasis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Filariasis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Onchocerciasis
- •References
- •25: Sexually Transmitted Infections
- •Introduction
- •STIs Associated with Genital Ulcers
- •Herpes Simplex Virus
- •Diagnosis
- •Treatment
- •Chancroid
- •Diagnosis
- •Treatment
- •Syphilis
- •Diagnosis
- •Treatment
- •Lymphogranuloma Venereum
- •Diagnosis
- •Treatment
- •Chlamydia
- •Diagnosis
- •Treatment
- •Gonorrhea
- •Diagnosis
- •Treatment
- •Trichomoniasis
- •Diagnosis
- •Treatment
- •Human Papilloma Virus
- •Diagnosis
- •Treatment
- •Scabies
- •Diagnosis
- •Treatment
- •References
- •26: Hematuria: Evaluation and Management
- •Introduction
- •Classification of Hematuria
- •Macroscopic Hematuria
- •Microscopic Hematuria
- •Dipstick Hematuria
- •Pseudohematuria
- •Factitious Hematuria
- •Menstruation
- •Aetiology
- •Malignancy
- •Urinary Calculi
- •Infection and Inflammation
- •Benign Prostatic Hyperplasia
- •Trauma
- •Drugs
- •Nephrological Causes
- •Assessment
- •History
- •Examination
- •Investigations
- •Dipstick Urinalysis
- •Cytology
- •Molecular Tests
- •Blood Tests
- •Flexible Cystoscopy
- •Upper Urinary Tract Evaluation
- •Renal USS
- •KUB Abdominal X-Ray
- •Intravenous Urography (IVU)
- •Computed Tomography (CT)
- •Retrograde Urogram Studies
- •Magnetic Resonance Imaging (MRI)
- •Additional Tests and Renal Biopsy
- •Intractable Hematuria
- •Loin Pain Hematuria Syndrome
- •References
- •27: Benign Prostatic Hyperplasia (BPH)
- •Historical Background
- •Pathophysiology
- •Patient Assessment
- •Treatment of BPH
- •Watchful Waiting
- •Drug Therapy
- •Interventional Therapies
- •Conclusions
- •References
- •28: Practical Guidelines for the Treatment of Erectile Dysfunction and Peyronie´s Disease
- •Erectile Dysfunction
- •Introduction
- •Diagnosis
- •Basic Evaluation
- •Cardiovascular System and Sexual Activity
- •Optional Tests
- •Treatment
- •Medical Treatment
- •Oral Agents
- •Phosphodiesterase Type 5 (PDE 5) Inhibitors
- •Nonresponders to PDE5 Inhibitors
- •Apomorphine SL
- •Yohimbine
- •Intracavernosal and Intraurethral Therapy
- •Intracavernosal Injection (ICI) Therapy
- •Intraurethral Therapy
- •Vacuum Constriction Devices
- •Surgical Therapy
- •Conclusion
- •Peyronie´s Disease (PD)
- •Introduction
- •Oral Drug Therapy
- •Intralesional Drug Therapy
- •Iontophoresis
- •Radiation Therapy
- •Surgical Therapy
- •References
- •29: Premature Ejaculation
- •Introduction
- •Epidemiology
- •Defining Premature Ejaculation
- •Voluntary Control
- •Sexual Satisfaction
- •Distress
- •Psychosexual Counseling
- •Pharmacological Treatment
- •On-Demand Treatment with Tramadol
- •Topical Anesthetics
- •Phosphodiesterase Inhibitors
- •Surgery
- •Conclusion
- •References
- •30: The Role of Interventional Management for Urinary Tract Calculi
- •Contraindications to ESWL
- •Complications of ESWL
- •PCNL Access
- •Instrumentation for PCNL
- •Nephrostomy Drains Post PCNL
- •Contraindications to PCNL
- •Complications of PCNL
- •Semirigid Ureteroscopy
- •Flexible Ureteroscopy
- •Electrohydraulic Lithotripsy (EHL)
- •Ultrasound
- •Ballistic Lithotripsy
- •Laser Lithotripsy
- •Ureteric Stents
- •Staghorn Calculi
- •Lower Pole Stones
- •Horseshoe Kidneys and Stones
- •Calyceal Diverticula Stones
- •Stones and PUJ Obstruction
- •Treatment of Ureteric Colic
- •Medical Expulsive Therapy (MET)
- •Intervention for Ureteric Stones
- •Stones in Pregnancy
- •Morbid Obesity
- •References
- •Anatomy and Function
- •Pathophysiology
- •Management
- •Optical Urethrotomy/Dilatation
- •Urethral Stents
- •Preoperative Assessment
- •Urethroplasty
- •Anastomotic Urethroplasty
- •Substitution Urethroplasty
- •Grafts Versus Flaps
- •Oral Mucosal Grafts
- •Tissue Engineering
- •Graft Position
- •Conclusion
- •References
- •32: Urinary Incontinence
- •Epidemiology and Risk Factors
- •Pathophysiology
- •Urge Incontinence
- •Conservative Treatments
- •Pharmacotherapy
- •Invasive/ Surgical Therapies
- •Stress Urinary Incontinence
- •Male SUI Therapies
- •Female SUI Therapies
- •Mixed Urinary Incontinence
- •Conclusions
- •References
- •33: Neurogenic Bladder
- •Introduction
- •Examination and Diagnostic Tests
- •History and Physical Examination
- •Imaging
- •Urodynamics (UDS)
- •Evoked Potentials
- •Classifications
- •Somatic Pathways
- •Brain Lesions
- •Cerebrovascular Accident (CVA)
- •Parkinson’s Disease (PD)
- •Multiple Sclerosis
- •Huntington’s Disease
- •Dementias
- •Normal Pressure Hydrocephalus (NPH)
- •Tumors
- •Psychiatric Disorders
- •Spinal Lesions and Pathology
- •Intervertebral Disk Prolapse
- •Spinal Cord Injury (SCI)
- •Transverse Myelitis
- •Peripheral Neuropathies
- •Metabolic Neuropathies
- •Pelvic Surgery
- •Treatment
- •Summary
- •References
- •34: Pelvic Prolapse
- •Introduction
- •Epidemiology
- •Anatomy and Pathophysiology
- •Evaluation and Diagnosis
- •Outcome Measures
- •Imaging
- •Urodynamics
- •Indications for Management
- •Biosynthetics
- •Surgical Management
- •Anterior Compartment Repair
- •Uterine/Apical Prolapse
- •Enterocele Repair
- •Conclusion
- •References
- •35: Urinary Tract Fistula
- •Introduction
- •Urogynecologic Fistula
- •Vesicovaginal Fistula
- •Etiology and Risk Factors
- •Clinical Factors
- •Evaluation and Diagnosis
- •Pelvic Examination
- •Cystoscopy
- •Imaging
- •Treatment
- •Conservative Management
- •Surgical Management
- •Urethrovaginal Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Ureterovaginal Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Vesicouterine Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Uro-Enteric Fistula
- •Vesicoenteric Fistula
- •Pyeloenteric Fistula
- •Urethrorectal Fistula
- •References
- •36: Urologic Trauma
- •Introduction
- •Kidney
- •Expectant Management
- •Endovascular Therapy
- •Operative Intervention
- •Operative Management: Follow-up
- •Reno-Vascular Injuries
- •Pediatric Renal Injuries
- •Adrenal
- •Ureter
- •Diagnosis
- •Treatment
- •Delayed Diagnosis
- •Bladder and Posterior Urethra
- •Bladder Injuries: Initial Management
- •Bladder Injuries: Formal Repair
- •Anterior Urethral Trauma
- •Fractured Penis
- •Penile Amputation
- •Scrotal and Testicular Trauma
- •Imaging
- •CT-IVP (CT with Delayed Images)
- •Technique
- •Cystogram
- •Technique
- •Retrograde Urethrogram (RUG)
- •Technique
- •Retrograde Pyelogram (RPG)
- •Technique
- •One-Shot IVP
- •Technique
- •References
- •37: Bladder Cancer
- •Who Should Be Investigated?
- •Epidemiology
- •Risk Factors
- •Role of Screening
- •Signs and Symptoms
- •Imaging
- •Cystoscopy
- •Urine Tests
- •PDD-Assisted TUR
- •Pathology
- •NMIBC and Risk Groups
- •Intravesical Chemotherapy
- •Intravesical Immunotherapy
- •Immediate Cystectomy and CIS
- •Radical Cystectomy with Pelvic Lymph Node Dissection
- •sexual function-preserving techniques
- •Bladder-Preservation Treatments
- •Neoadjuvant Chemotherapy
- •Adjuvant Chemotherapy
- •Preoperative Radiotherapy
- •Follow-up After TUR in NMIBC
- •References
- •38: Prostate Cancer
- •Introduction
- •Epidemiology
- •Race
- •Geographic Variation
- •Risk Factors and Prevention
- •Family History
- •Diet and Lifestyle
- •Prevention
- •Screening and Diagnosis
- •Current Screening Recommendations
- •Biopsy
- •Pathology
- •Prognosis
- •Treatment of Prostate Cancer
- •Treatment for Localized Prostate Cancer (T1, T2)
- •Radical Prostatectomy
- •EBRT
- •IMRT
- •Brachytherapy
- •Treatment for Locally Advanced Prostate Cancer (T3, T4)
- •EBRT with ADT
- •Radical Prostatectomy
- •Androgen-Deprivation Therapy
- •Summary
- •References
- •39: The Management of Testis Cancer
- •Presentation and Diagnosis
- •Serum Tumor Markers
- •Primary Surgery
- •Testis Preserving Surgery
- •Risk Stratification
- •Surveillance Versus Primary RPLND
- •Primary RPLND
- •Adjuvant Treatment for High Risk
- •Clinical Stage 1 Seminoma
- •Risk-Stratified Adjuvant Treatment
- •Adjuvant Radiotherapy
- •Adjuvant Low Dose Chemotherapy
- •Primary Combination Chemotherapy
- •Late Toxicity
- •Salvage Strategies
- •Conclusion
- •References
- •Index
|
|
|
462 |
|
|
|
|
||
|
|
Practical Urology: EssEntial PrinciPlEs and PracticE |
||
and maximal urethral pressures have been mea- |
Table 33.3. therapeutic strategies based on underlying bladder |
|||
sured with hypocontractility causing residual |
or outlet pathology. (a) drug therapies. (B) surgeries/devices. |
|||
urines. In studies of women with LUTS after |
therapies often combined |
|
||
simple hysterectomy, 47% have DO, 37% outlet |
A. |
|
||
obstruction, and 25% SUI, suggesting both pel- |
Bladder |
Outlet |
||
vic support injury and changes to the detrusor.48 |
||||
overactive |
increased resistance |
|||
Similar to colorectal surgeons, gynecologic |
||||
oncologists are using nerve-sparing techniques |
• Antimuscarinics |
• Alpha-1 antagonists |
||
when feasible to avoid creating a neurogenic |
• Tricyclic |
• Dantrolene, benzodiaz- |
||
bladder. |
||||
|
epines, tizanidine |
|||
|
|
|
||
Treatment |
• Investigational- |
• Botulinum toxin |
||
Botulinum toxin to |
to EUs |
|||
|
|
|||
detrusor
Management of patients with neurogenic bladders is complex by nature of the social, economic, overall disability, and cognitive issues beyond urologic considerations. Many of the urologic complications are preventable and arise from lack of monitoring or poor patient compliance with medications, clean intermittent catheterization (CIC), or periodic follow-up with urinalyses/cultures and renal ultrasound. Physicians should strongly counsel patients early in the diagnosis of warning signs, abstinence from smoking because of heightened risk of malignancies, the need for periodic followup, and prevention of obesity which may complicate future reconstruction or diversion.
In general, therapies follow a noninvasive and conservative to invasive progression. Issues such as upper tract deterioration or recurrent febrile episodes often require more aggressive intervention. The goals of therapy in order of importance include preventing upper tract deterioration, reducing urinary infections, and improving the quality of life of the patient. It is important to identify family members or care givers who can participate in their care, since coexistent depression and lack of motor or cognitive function may impair the treatment plan.
Table 33.3 outlines therapy in each quadrant of dysfunction. For every functional problem (detrusor overactive/underactive and outlet increased resistance/reduced resistance), a behavioral, pharmacologic device, or surgical approach can be considered.
For overactive detrusor (OAB, urge UI, reduced compliance), pelvic muscle exercises, biofeedback, and time voiding with fluid management represent conservative measures as well as adjustment of medications that may worsen the condition such as diuretics. Antimuscarinics are the mainstay of pharmaco-
Underactive |
reduced resistance |
• Bethanechol |
• Alpha agonist |
|
• Tricyclic |
|
• Duloxetine |
B. |
|
Bladder |
Outlet |
overactive |
increased resistance |
• Interstim, |
• Urolume stent |
neuromodulation |
|
• Augmentation |
• Sphincterotomy |
cystoplasty |
|
• Divert |
• TURBN |
Underactive |
reduced resistance |
• Ileovesicostomy |
• Bulking agent |
• Mitrofanoff |
• AUS |
• Divert |
• Retropubic suspension/ |
|
slings |
• Myoplasty |
• Closure of bladder neck |
|
• Tricyclic |
|
• Duloxetine |
logic therapy although tricyclics may have a limited role. Botulinum toxin injections into the detrusor can be tried as a nonapproved therapy. InterStim or other forms of neuromodulation are recommended after failure of antimuscarinics and conservative measures. For refractory cases, especially in whom reduced compliance, low capacity, and high DLLPs lead to upper tract changes, augmentation cystoplasty can be performed. Neurolytic procedures have fallen out of favor in part due to subsequent
463
nEUrogEnic BladdEr
neuroplasticity leading to worsening or unpre- |
Summary |
|||||
|
|
|||||
dictable LUT changes. |
|
|
|
|||
For the underactive detrusor (impaired con- |
The lower urinary tract is a window into the |
|||||
tractility, areflexia), conservative measures such |
||||||
nervous system. Neurologic disease often causes |
||||||
as double voiding, Valsalva voiding, and pelvic |
||||||
failure to retain urine or empty the bladder, |
||||||
muscle relaxation are often of limited use. The |
||||||
sometimes both. Therapy must be planned to |
||||||
mainstay therapy is CIC. However, if this is not |
||||||
preserve upper tracts, avoid urinary infections, |
||||||
feasible, urinary diversion with an ileal conduit |
||||||
and maintain an acceptable quality of life. Such |
||||||
or ileovesicostomy can be performed.Indwelling |
||||||
planning may be complex in view of the social, |
||||||
catheters especially suprapubic tubes are gain- |
||||||
economic, cognitive, and motor deficits that |
||||||
ing resurgence in popularity since studies are |
||||||
patients with neurogenic bladder present with. |
||||||
showing relative safety in this era of frequent |
||||||
A stepwise approach to management with peri- |
||||||
monitoring, antibiotics, and improved catheter |
||||||
odic surveillance offers unique challenges to the |
||||||
care.49 However, long-term sequelae decades |
||||||
urologist. |
||||||
later may prove that 10-year data is insufficient |
||||||
|
|
|||||
to make long-term recommendations. |
|
|
||||
For increased outlet resistance (DSD, DISD) |
References |
|||||
pelvic muscle relaxation is often ineffective |
||||||
but can be tried. Alpha adrenergic antagonists |
1. |
Lai HH, Boone TB. Urologic management of spinal cord |
||||
might slightly reduce resistance through local |
||||||
|
injury. AUA Update Ser. 2008;27:234-243 |
|||||
and spinal mechanisms. Antispasmodics such |
|
|||||
2. |
McGuire EJ, Woodside JR, Borden TA. Prognostic value |
|||||
as baclofen, benzodiazepines, and tizanidine |
||||||
|
of urodynamic testing in myelodysplasia patients. J Urol. |
|||||
are mentioned, but no efficacy data is available |
|
1983;126:205-210 |
||||
for oral administration. Injections of botuli- |
3. |
Wein A. Classification of neurogenic voiding dysfunc- |
||||
num toxin A into the EUS has a role but |
|
tion. J Urol. 1981;125:605-609 |
||||
requires retreatment and may be insufficient |
4. |
Steers WD, Gray M. A simple method for teaching about |
||||
to allow complete emptying. Urethral stents |
|
voiding disorders. BJU Int. 2006;97(2):238-242 |
||||
5. |
Su HC, Polak JM, Mulderry PK, et al. Calcitonin generated |
|||||
have been used with variable shortand long- |
||||||
|
peptide immunoreactivity in afferent neurons supplying |
|||||
term success.50 Traditional therapy for DSD is |
|
|||||
|
the urinary tract: combined retrograde tracing and |
|||||
a sphincterotomy with a hot knife, resecto- |
|
immunohistochemistry. Neuroscience. 1986;18: 727-747 |
||||
scope, or laser. However, long-term efficacy is |
6. |
Vizzard MA, Erdman SL, de Groat WC. Increased expres- |
||||
50%. In |
part, |
failures even |
with repeated |
|
sion of neuronal nitric oxide synthase in bladder affe- |
|
sphincterotomies may be due to inadequate |
|
rent pathways following chronic bladder irritation. |
||||
|
J Comp Neurol. 1996;370:191-202 |
|||||
resection |
due |
to extensive |
spasticity and |
|
||
7. |
Vizzard MA. Up-regulation of pituitary adenylate |
|||||
hypertrophy of the entire pelvic floor.Moreover, |
||||||
|
cyclase-activating polypeptide in urinary bladder path- |
|||||
some preserved outlet resistance may be nec- |
|
ways after chronic cystitis. J Comp Neurol. 2000;420: |
||||
essary to trigger a spinal micturition reflex. |
|
335-348 |
||||
Paradoxically, complete elimination of outlet |
8. |
Chess-Williams R. Muscarinic receptors of the urinary |
||||
resistance may not allow triggering of a sus- |
|
bladder: detrusor, urothelial and pre-junctional. |
||||
|
Autonom Autacoid Pharmacol. 2002;22:133-145 |
|||||
tained or repeated reflex thereby causing |
|
|||||
9. |
Andersson KE, Wein AJ. Pharmacology of the lower |
|||||
increases in residual urine. |
|
|||||
|
|
urinary tract: basis for current and future treatments of |
||||
For reduced outlet resistance due to intrinsic |
|
urinary incontinence. Pharmacol Rev. 2004;56(4):581-631 |
||||
sphincter deficiency, pelvic muscle exercises can |
10. |
Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB. |
||||
be attempted. Bulking agents, except in women |
|
Botulinum-A toxin as a treatment of detrusor-sphincter |
||||
with impaired contractility and ISD, have a lim- |
|
dyssynergia: a prospective study in 24 spinal cord injury |
||||
ited role. Drugs such as alpha adrenergic ago- |
|
patients. J Urol. 1996;155(3):1023-1029 |
||||
11. |
Patel AK, Patterson JM, Chapple CR. Botulinum toxin |
|||||
nists are rarely effective and may lead to |
||||||
|
injections for neurogenic and idiopathic detrusor over- |
|||||
hypertension or stroke. Duloxetine may also |
|
activity: a critical analysis of results. Eur Urol. 2006; |
||||
have limited utility to raise outlet resistance.51 |
|
50(4):684-710 |
||||
Fascial or midurethral slings can be utilized and |
12. |
Holstege G, Mouton LJ. Central nervous system control of |
||||
for severe ISD a circumferential sling may be |
13. |
micturition. Int Rev Neurobiol. 2003;56:123-145 |
||||
needed. Sometimes, closure of the urethra or |
Nadelhaft PL,Vera JPC, Miselis RR. Central nervous sys- |
|||||
|
tem neurons labelled following the injection of pseudo- |
|||||
bladder neck is required with either continent |
|
|||||
|
rabies virus into the rat urinary bladder. Neurosci Lett. |
|||||
or supravesical diversion. |
|
|
||||
|
|
1992;143:271-274 |
||||
464
Practical Urology: EssEntial PrinciPlEs and PracticE
14.Klausner AP, Streng T, Na YG, et al. The role of corticotropin releasing factor and its antagonist, astressin, on micturition in the rat. Auton Neurosci. 2005;123:26-35
15.Link C, Lutfey KE, Steers W, McKinlay JB. Is abuse causally related to urologic symptoms? Results from the Boston Area Community Health (BACH) survey. Eur Urol. 2007;52:397-456
16.Tibaek S, Gard G, Klarskov P, Iversen HK, Dehlendorff C, Jensen R. Prevalence of lower urinary tract symptoms (LUTS) in stroke patients: a cross-sectional, clinical survey. Neurourol Urodyn. 2008;27:763-771
17.Kolominsky-Rabas PL, Hilz MJ, Neundoerfer B, Heuschmann PU. Impact of urinary incontinence after stroke: results from a prospective population-based stroke register. Neurourol Urodyn. 2003;22:322-327
18.Marinkovic S,Badlani G.Voiding and sexual dysfunction after cerebrovascular accidents. J Urol. 2001;165:359-370
19.Pavlakis AJ, Siroky MB, Goldstein I, Krane RJ. Neurourologic findings in Parkinson’s disease. J Urol. 1983; 129:80-83
20.Chandiramani VA, Palace J, Fowler CJ. How to recognize patients with Parkinsonism who should not have urological surgery. Br J Urol. 1997;80:100-104
21.Salinas JM, Berger Y, De La Rocha RE, Blaivas JG. Urologic evaluation in the Shy Drager syndrome. J Urol. 1986;135:741-743
22.Sakakibara R, Hattori T, Uchiyama T, Yamanishi T. Videourodynamic and sphincter motor unit potential analyses in Parkinson’s disease and multiple system atrophy. J Neurol Neurosurg Psychiatry. 2001;71: 600-606
23.Palace J, Chandiramani VA, Fowler CJ.Value of sphincter electromyography in the diagnosis of multiple system atrophy. Muscle Nerve. 1997;20:1396-1403
24.Sakakibara R, Hattori T, Kita K, Arai K, Yamanishi T, Yasuda K. Stress induced urinary incontinence in patients with spinocerebellar degeneration. J Neurol Neurosurg Psychiatry. 1998;64:389-391
25.Litwiller SE, Frohman EM, Zimmern PE. Multiple sclerosis and the urologist. J Urol. 1999;161(3):743-757.
26.Mori S, Kojima M, Sakai Y, Nakajima K. Bladder dysfunction in dementia patients showing urinary incontinence; evaluation with cystometry. Jpn J Geriartr. 1999; 36:489-494
27.Sakakibara R, Kanda T, Sekido T, et al. Mechanism of bladder dysfunction in idiopathic normal pressure hydrocephalus. Neurourol Urodyn. 2008;27:507-510
28.Bech RA, Waldemar G, Gjerris F, Klinken L, Juhler M. Shunting effects in patients with idiopathic normal pressure hydrocephalus: correlation with cerebral and leptomeningeal biopsy findings. Acta Neurochir Wien. 1999;141:633-639
29.Lu CJ, Tune LE. Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. Am J Geriatr Psychiatry. 2003;11:458-461
30.McNeal DM, Hawtrey CE, Wolraich ML, Mapel JR. Symptomatic neurogenic bladder in a cerebral palsy population. Dev Med Child Neurol. 1983;25:612-616
31.Drigo F, Seren W, Artibani AM, et al. Neurogenic vesicourethral dysfunction in children with cerebral palsy. Ital J Neurol Sci. 1988;80:151
32.Leach GE, Farsaii A, Kark P, Raz S. Urodynamic manifestations of cerebellar ataxia. J Urol. 1982;128:348-350
33.Chami N, Miladi HM, Ben S, et al. Continence disorders in hereditary spinocerebellar degeneration: urodynamic findings in 55 cases. Acta Neurol Belg. 1984; 84:194-203
34.Vézina JL, Fox AJ. Double blind study of the toxicity of intrathecal iopamidol and metrizamide in lumbar myelography. J Can Assoc Radiol. 1984;35(3):257-258
35.Gil-Nagel A, Gapany S, Blesi K, Villanueva N, Bergen D. Incontinence during treatment with gabapentin. Neuro logy. 1997;48:1467-1471
36.Maurice-Williams RS. Micturition symptoms in frontal tumors. J Neurol Neurosurg Psychiatry. 1974; 37:431-436
37.Zorn B, Montgomery H, Gray M, Steers W. Urge urinary incontinence and depression. J Urol. 1999; 162:82-84
38.Weiss JP, Blaivas JG. Nocturia. J Urol. 2000;163(1):5-12
39.Delamarter RB, Bohlman HH, Bodner D, et al. Urologie function after experimental cauda equine. Spine. 1990;15:864-870
40.Fanciullacci F, Sandri S, Politi P, Zanollo A. Clinical, urodynamic and neurophysiological findings in patients with neuropathic bladder. Paraplegia. 1989;27:354-358
41.Bartolin Z, Vilendecic M, Derezic D. Bladder function after surgery for lumbar intervertebral disk protrusion. J Urol. 1999;161:1885-1887
42.Sakakibara R, Hattori T, Yasuda K, Yamanishi T. Micturitional disturbances in acute transverse myelitis. Spinal Cord. 1996;34:481-485
43.Berger Y, Blavis JG, Oliver L. Urinary dysfunction in transverse myelitis. J Urol. 1990;144:103-105.
44.Hanus T. Other diseases (transverse myelitis, tropical spastic paraparesis, progressive multifocal leukoencephalopathy, Lyme’s disease). In: Corcos J, Schick E, eds.
Textbook of the Neurogenic Bladder. London: Informa; 2003:312-326
45.Broseta E, Osca JM, Morera J, et al. Urological manifestations of herpes zoster. Eur Urol. 1993;24:244-247
46.Anger JT, Saigal CS, Litwin MS. The prevalence of urinary incontinence among community dwelling adult women: results from the National Health and Nutrition Examination Survey. J Urol. 2006;175(2):601-604
47.Brown JS, Wessels H, Chancellor MB, et al. Urologic outcomes of diabetes. Diabetes Care. 2005;28(1):177-185
48.Kershen RT, Boone TB. Peripheral neuropathies of the lower urinary tract following pelvic surgery and radiation therapy. In: Corcos J, Schick E, eds. Textbook of the Neurogenic Bladder. London: Informa; 2003: 246-255
49.Feifer A, Corcos J. Contemporary role of suprapubic cystotomy in the treatment of neuropathic bladder dysfunction in spinal cord injured patients. Neurourol Urodyn. 2008;27:475-479
50.Chancellor MB, Gajewski J, Ackman CFD, et al. Longterm followup of the North American multicenter UroLume trial for the treatment of external detrusorsphincter dyssynergia. J Urol. 1999;161:1545-1550
51.Norton PA, Zinner NR, Yalcin I, Bump RC. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol. 2002;187:40-48